


Tom Pilcher Head of Country Coordination Department of Health and Social Care

Claire Gordon Lead Clinical Microbiologist, Fleming Fund Management Agent, Mott MacDonald

November 2020







## Who we are

The Fleming Fund is a £265m UK aid programme building global partnerships to improve AMR surveillance.

We share the best of UK and international expertise to strengthen national public health capabilities in surveillance.

We enable countries to improve the collection and use of antimicrobial resistance (AMR) data in line with their National Actions Plans so governments and the global community can take action to improve patient health, inform national health policies and warn of emerging threats.

## Where we work

#### **West Africa:**

- Ghana
- Nigeria
- Senegal
- Sierra Leone

#### **South Asia:**

- Bangladesh
- Bhutan
- Nepal
- Pakistan
- Sri Lanka

#### **South East Asia:**

- Indonesia
- Laos
- Myanmar


#### **East and Southern Africa:**

- Eswatini
- Kenya
- Malawi
- Tanzania
- Uganda
- Zambia
- Zimbabwe





## How we work: Programme Principles



#### **One Health**

Because bacteria spread freely around the environment, we promote a multi-sectoral response that includes human health, animal health and environmental health.



## **Alignment**

We ensure our funding aligns with broader global initiatives like the World Health Organization's Global Action Plan on AMR.





We ensure projects and activities are bespoke designed with national institutions to support national systems with sustainability the primary consideration.



## **Country Ownership**

Projects are designed with national governments to support implementation of National Action Plans, so that all activities contribute to national health system strengthening.



## What we do

#### **OUR AIMS**



**Build partnerships** across sectors, governments and organisations



Equip countries to collect, share and use data on drug resistance



Encourage clinicians and farmers to use antibiotics better



Encourage governments to invest in tackling AMR for a sustainable future



Encourage policymakers to make AMR a policy priority

#### **OUR ACTIVITIES**



Support strong national AMR governance



Develop AMR workforce capacity



Establish **laboratory capacity** and **surveillance systems** 



Improve **awareness** and understanding of AMR



Establish national, regional and **global** solidarity on AMR.



## **Our Investments**

# INDEPENDENT EVALUATION



# IMPROVING AWARENESS AND DATA USE







# BUILDING THE ENABLING ENVIRONMENT

including AMR governance and global solidarity





# STRENGTHENING NATIONAL SURVEILLANCE SYSTEMS & AMR WORKFORCE CAPACITY







#### Itad Independent Evaluation

Commonwealth Partnerships for Antimicrobial Stewardship

ODI Economic Fellowships

South Centre

GRAM Global Burden of Disease

#### World Health Organization

Food and Agriculture Organization World Organization for Animal Health

FAO International Reference Centre FIND Substandard and Falsified Medicines

#### **MANAGEMENT AGENT MOTT MACDONALD**

Fellowship Schemes

Open University Online Learning

**Country Grants** 

**Regional Grants** 



## Fleming Fund Country Support

## Country grant


- Focus on supporting the surveillance component of the NAP
- Intersectoral governance and coordination
- Development of laboratories, human resources, reporting systems

#### **Fellowships**

Advanced workforce development

## **Regional Grants**

Standardising approaches for training, EQA, protocols etc.






## Fleming Fund Design

#### Country Grants are closely aligned with Tripartite Programmes

- In Human Health:
- GLASS-AMR
  - Passive surveillance for drug-resistant bacterial infection
    - Development of clinical diagnostic microbiology services
  - GLASS priority samples, pathogens, and bug-drug combinations
  - Stepwise approach guided by the LSHTM roadmap
- AMU as per WHO methodology





#### In Animal Health

- Active surveillance
  - Initial focus on poultry
  - Salmonella and E. coli as important transboundary organisms
  - Stepwise approach as per poultry protocol, progressing in line with FAO protocol
- AMU / AMC reporting in line with OIE




A Protocol for Active AMR Surveillance in Poultry

A Protocol for Active AMR Surveillance in Poultry | The Fleming Fund | 1

Towards a One Health AMR Surveillance System: protocol for active AMR surveillance in commercial broiler and layer chicken populations for the Fleming Fund Grants Programme.

Version 2

10 December 2019





## **Baseline findings: Governance**

## Situation as of 2017/2018

- All countries had an AMR-NAP, or a draft awaiting approval
- All except one had established an AMR coordination committee
- Only a minority of AMRCCs had designated specific subcommittees or TWGs for NAP implementation
- Even fewer were meeting regularly or undertaking activities
- Only one country received government funding to support AMRCC meetings / activities.

| Region                         | NAP | AMRCC<br>established | TWGs<br>established | AMRCC<br>Functional<br>* | Government<br>funding for<br>AMRCC<br>activities |
|--------------------------------|-----|----------------------|---------------------|--------------------------|--|
| West<br>Africa                 | Υ   | Υ                    | Υ                   | N                        | N  |
|                                | Υ   | Υ                    | Υ                   | Υ                        | Р  |
|                                | Υ   | Υ                    | Υ                   | N                        | N  |
|                                | Υ   | Υ                    | N                   | N                        | N  |
|                                | Υ   | Υ                    | Υ                   | Р                        | N  |
| East and<br>Southern<br>Africa | Υ   | Υ                    | Υ                   | Р                        | N  |
|                                | Υ   | Υ                    | Υ                   | Υ                        | N  |
|                                | Υ   | Υ                    | Υ                   | Р                        | N  |
|                                | Υ   | Υ                    | Υ                   | Υ                        | N  |
|                                | Υ   | Υ                    | N                   | Υ                        | N  |
|                                | Υ   | Υ                    | Υ                   | Υ                        | N  |
|                                | Υ   | Υ                    | Р                   | Р                        | N  |
| South Asia                     | Υ   | Р                    | N                   | N                        | N  |
|                                | Υ   | Υ                    | N                   | Р                        | N  |
|                                | Υ   | Υ                    | N                   | N                        | N  |
|                                | Υ   | Υ                    | N                   | Р                        | N  |
|                                | Υ   | Υ                    | Υ                   | Р                        | N  |
| South East<br>Asia             | Υ   | Y                    | Р                   | Р                        | N  |
|                                | Р   | Υ                    | N                   | N                        | N  |
|                                | Р   | N                    | N                   | N                        | N  |
|                                | Υ   | Υ                    | N                   | N                        | N  |
|                                | Υ   | Υ                    | N                   | Р                        | N  |
|                                | Υ   | Υ                    | N                   | Р                        | N  |


<sup>\*</sup>Functional: agreed ToRs, regular meetings, undertaking activities



## **Human Health laboratory capacity (n=156)**

- More than half require structural renovations and / or improvements in utilities (water, electrical supply, IT)
- Fewer than 40% meet requirements for BSL 2 (despite operating at this level) – e.g. only about 50% have adequate autoclave capacity.
- Regional differences: generally greater needs WA->ESA->SA->SEA








## HH Baseline: Bacteriology capacity - Baseline (n=156)

- Majority of sites experience stockouts
- >50% do not have a reliable source of horse or sheep blood
- Over 70% provide a
   blood culture service, of
   those, but 20% of those
   are performing manual
   cultures only




## Non-human health laboratory capacity

Baseline (n=78)

Similar challenges in other sectors

Most sites need improvements in infrastructure, biosafety and basic bacteriology





## **Progress**

Active Country Grants

**@**20

Active Regional Grants

• 11

**Active Fellows** 

•118

- 161 laboratories currently reporting, including 111 human health and 50 animal, aquaculture and environmental health.
- 14 Fleming Fund countries enrolled in GLASS. (up from 7 in 2016). 9 Fleming Fund countries submitted data to GLASS. (up from 2 in 2016)
- 155 countries have supplied data on antimicrobial use in animals to OIE database.
- Mapped out the location and sources of AMR and AMU data across Africa and Asia
- 142 fellowships are approved in 20 countries.







## Learning

#### Realism:

Time to build the Fleming Fund platform in a way which ensured <u>country ownership</u> and <u>sustainability</u>. Sustainable surveillance systems and realising benefits take time.

## **Coordination and alignment:**


Coordination is resource-intensive but critical.

.

## Leadership:

We need to continue to demonstrate the value of Global Health Security including through flagship investments like the Fleming Fund. Keeping AMR as a priority for international engagement is key

## **Building demand for data**







## Thank you



